Seattle (ots/PRNewswire) - - First Detailed Results from SWORD Clinical Trial Program Show Investigational Two-drug Combination as Effective as Three- or Four-drug Regimens as Maintenance Therapy in Patients who have Already Achieved Viral Suppression Janssen Sciences Ireland UC (Janssen) announced positive results ...
Cork, Ireland (ots/PRNewswire) - Includes several late breaking and oral presentations from across R&D pipeline Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens Janssen Sciences Ireland UC and certain Janssen affiliates* today announced it will present thirteen abstracts ...
Cork, Ireland (ots/PRNewswire) - Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, (Janssen) announced 32-week data from an ongoing phase IIb study. A ...
Cork, Ireland (ots/PRNewswire) - Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development ...
Cork, Ireland (ots/PRNewswire) - Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced that Phase IIb data studying a combination regimen of ...